Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

[Business Wire] – Pfizer Inc. announced today the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment Psoriasis Trials program at the 73rd American Academy of Dermatology . . . → Read More: Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials Similar Articles: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults Market Update (NASDAQ:GILD): UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment